NCT05595447View on ClinicalTrials.gov

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

October 18, 2025

Study Completion Date

October 18, 2025

Conditions
Hodgkin LymphomaRefractory Hodgkin LymphomaRelapsed Hodgkin's Disease, Adult
Interventions
DRUG

Brentuximab Vedotin 50 MG [Adcetris]

Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1

Trial Locations (1)

37660

RECRUITING

Hospital Regional Alta Especialidad Bajio, León

All Listed Sponsors
collaborator

Universidad de Guanajuato

OTHER

lead

Hospital Regional de Alta Especialidad del Bajio

OTHER